WuXi Biologics (Cayman) Inc. (WXXWY)
WuXi Biologics (Cayman) Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wuxi, JS, CN. The stock last traded at $11.61, down 0.60% on the session, giving a market capitalisation of $23.84B. On trailing twelve-month figures it carries a trailing P/E of 32.98, a net margin of 22.5%. Its beta of 0.60 implies it has historically moved less than the broad market.
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical trials and production of biologics, produces and distributes medical goods, operates a contract development and manufacturing organization (CDMO) for vaccines, and supplies essential materials to the industry. Founded in 2014, WuXi Biologics is based in Wuxi, China, and maintains strategic alliances with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc.
WuXi Biologics (Cayman) Inc. is most often compared with the following Healthcare names: